Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Express Scripts Holding Company (ESRX) Shuts Out Gilead Sciences Inc. (GILD) On A Cheaper Hepatitis C Treatment

Express Scripts Holding Company (NASDAQ:ESRX) desire to accord Hepatitis C patients with  what it believes to be the best of care has seen it ink a discounted deal with AbbVie Inc. (NYSE:ABBV) for its Viekira Pak treatment. The agreement according to CNBC’s, Meg Tirrell, cuts Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) drugs that were on sale by the U.S largest pharmacy.

Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD)’s Sovaldi has been at the center of controversy since being approved last year over what was believed to be overpricing. The drug goes on sale for $84,000 for a 12-week treatment, which has allowed the company to generate $8 billion worth in sales in the first three-quarters of the year.

“Payers have been pushing back against this and now Express Scripts Holding Company (NASDAQ:ESRX) is saying there is this new drug that just got approved on Friday from AbbVie Inc. (NYSE:ABBV). They’ve cut a significant discount to Express Scripts in order to get exclusive billing on the formulary,” said Mrs. Tirrell.

Patients with Genotype 1 will now be able to get the AbbVie Inc. (NYSE:ABBV) drug having been made available on Express Scripts National Preferred Formulary that covers about 25 million Americans. Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson and Johnson drug Olysio will consequently be excluded from the formulary starting January 1. Patients who had already begun their treatment before the date will continue to be issued with the suspended drugs.

Industry players have in the recent months been complaining that Gilead and JNJ were overcharging patients taking into consideration the amount of revenue that has been generated over the past three-quarters. The move by Express Scripts to suspend the drugs may also affect the development of other drugs for therapeutic purposes based on the fact that companies will start questioning whether they will be reimbursed for the hard work.

The fact that Gilead Sciences, Inc. (NASDAQ:GILD) drug has a good track record of curing Hepatitis C has removed some of the pressure on its pricing when compared to other available options that are expensive.  Express Scripts Holding Company (NASDAQ:ESRX) has not issued details of the amount of discounts that it will be offering for the AbbVie Inc. (NYSE:ABBV) drug that is to be sold through its Accredo specialty pharmacy.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!